FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386476503> ?p ?o ?g. }

• W4386476503 endingPage "367" @default.
• W4386476503 startingPage "365" @default.
• W4386476503 abstract "Direct oral anticoagulants (DOACs) have demonstrated similar or better efficacy to warfarin in reducing stroke and systemic embolic events in large-scale prospective trials. 1 Connolly SJ Ezekowitz MD Yusuf S Eikelboom J Oldgren J Parekh A Pogue J Reilly PA Themeles E Varrone J Wang S Alings M Xavier D Zhu J Diaz R Lewis BS Darius H Diener HC Joyner CD Wallentin L RE-LY Steering Committee and InvestigatorsDabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-1151 Google Scholar , 2 Patel MR Mahaffey KW Garg J Pan G Singer DE Hacke W Breithardt G Halperin JL Hankey GJ Piccini JP Becker RC Nessel CC Paolini JF Berkowitz SD Fox KA Califf RM ROCKET AF InvestigatorsRivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883-891 Google Scholar , 3 Granger CB Alexander JH McMurray JJV Lopes RD Hylek EM Hanna M Al-Khalidi HR Ansell J Atar D Avezum A Bahit MC Diaz R Easton JD Ezekowitz JA Flaker G Garcia D Geraldes M Gersh BJ Golitsyn S Goto S Hermosillo AG Hohnloser SH Horowitz J Mohan P Jansky P Lewis BS Lopez-Sendon JL Pais P Parkhomenko A Verheugt FWA Zhu J Wallentin L Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-992 Google Scholar , 4 Giugliano RP Ruff CT Braunwald E Murphy SA Wiviott SD Halperin JL Waldo AL Ezekowitz MD Weitz JI Špinar J Ruzyllo W Ruda M Koretsune Y Betcher J Shi M Grip LT Patel SP Patel I Hanyok JJ Mercuri M Antman EM ENGAGE AF-TIMI 48 InvestigatorsEdoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369: 2093-2104 Google Scholar In addition, these trials demonstrated either noninferiority or superiority in reducing bleeding events compared with warfarin. To treat high-risk patients with atrial fibrillation (AF) and avoid bleeding in low-risk patients, current guidelines recommend oral anticoagulants in high-risk patients with AF with CHA2DS2VASc scores of ≥2 in men and ≥3 in women. 5 January CT Wann LS Calkins H Chen LY Cigarroa JE Cleveland JC Ellinor PT Ezekowitz MD Field ME Furie KL Heidenreich PA Murray KT Shea JB Tracy CM Yancy CW 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019; 140: e125-e151 Google Scholar ,6 Hindricks G Potpara T Dagres N Arbelo E Bax JJ Blomstrom-Lundqvist C Boriani G Castella M Dan GA Dilaveris PE Fauchier L Filippatos G Kalman JM La Meir M Lane DA Lebeau JP Lettino M Lip GYH Pinto FJ Thomas GN Valgimgli M Van Gelder IC Van Putte BP Watkins CL the European Society of Cardiology Scientific Document Group2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42: 373-498 Google Scholar In spite of these well-known recommendations, registries and systemic reviews suggest that 20% to 50% of high-risk patients with AF are not taking an oral anticoagulant. 7 Hsu JC Maddox TM Kennedy KF Katz DF Marzec LN Lubitz SA Gehi AK Turakhia MP Marcus GM Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk: insights from the NCDR PINNACLE Registry. JAMA Cardiol. 2016; 1: 55-62 Google Scholar ,8 Naccarelli GV Ruzieh M Wolbrette DL Sendra-Ferrer M van Harskamp J Bentz B Caputo G McConkey N Mills K Wasemiller S Plamenac J Leslie D Glasser FD Abendroth TW Oral anticoagulation use in high-risk patients is improved by elimination of false positive and inactive atrial fibrillation cases. Am J Med. 2021; 134: e366-e373 Google Scholar Data suggests that this treatment gap has not been significantly reduced with the commercial release of DOACS 9 Marzec LN Wang J Shah ND Chan PS Ting HH Gosch KL Hsu JC Maddox TM Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation. J Am Coll Cardiol. 2017; 69: 2475-2484 Google Scholar even though most new patients are being treated with DOACS." @default.
• W4386476503 created "2023-09-07" @default.
• W4386476503 creator A5020566430 @default.
• W4386476503 date "2023-11-01" @default.
• W4386476503 modified "2023-10-11" @default.
• W4386476503 title "Direct Oral Anticoagulants: Patients Benefit When Prescribers Get the Message" @default.
• W4386476503 cites W1975709693 @default.
• W4386476503 cites W2012050489 @default.
• W4386476503 cites W2096246254 @default.
• W4386476503 cites W2097854437 @default.
• W4386476503 cites W2136489990 @default.
• W4386476503 cites W2162508946 @default.
• W4386476503 cites W2298220628 @default.
• W4386476503 cites W2566947560 @default.
• W4386476503 cites W2616300024 @default.
• W4386476503 cites W2747775477 @default.
• W4386476503 cites W2809373811 @default.
• W4386476503 cites W2957544571 @default.
• W4386476503 cites W3034331236 @default.
• W4386476503 cites W3082188176 @default.
• W4386476503 cites W3084947671 @default.
• W4386476503 cites W3115682543 @default.
• W4386476503 cites W4205741735 @default.
• W4386476503 cites W4327968167 @default.
• W4386476503 cites W4367056731 @default.
• W4386476503 cites W4386613422 @default.
• W4386476503 doi "https://doi.org/10.1016/j.amjcard.2023.08.089" @default.
• W4386476503 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37679191" @default.
• W4386476503 hasPublicationYear "2023" @default.
• W4386476503 type Work @default.
• W4386476503 citedByCount "0" @default.
• W4386476503 crossrefType "journal-article" @default.
• W4386476503 hasAuthorship W4386476503A5020566430 @default.
• W4386476503 hasConcept C126322002 @default.
• W4386476503 hasConcept C164705383 @default.
• W4386476503 hasConcept C2776301958 @default.
• W4386476503 hasConcept C2779161974 @default.
• W4386476503 hasConcept C71924100 @default.
• W4386476503 hasConceptScore W4386476503C126322002 @default.
• W4386476503 hasConceptScore W4386476503C164705383 @default.
• W4386476503 hasConceptScore W4386476503C2776301958 @default.
• W4386476503 hasConceptScore W4386476503C2779161974 @default.
• W4386476503 hasConceptScore W4386476503C71924100 @default.
• W4386476503 hasFunder F4320333195 @default.
• W4386476503 hasLocation W43864765031 @default.
• W4386476503 hasLocation W43864765032 @default.
• W4386476503 hasOpenAccess W4386476503 @default.
• W4386476503 hasPrimaryLocation W43864765031 @default.
• W4386476503 hasRelatedWork W131995492 @default.
• W4386476503 hasRelatedWork W1531601525 @default.
• W4386476503 hasRelatedWork W2748952813 @default.
• W4386476503 hasRelatedWork W2899084033 @default.
• W4386476503 hasRelatedWork W2948807893 @default.
• W4386476503 hasRelatedWork W3173606202 @default.
• W4386476503 hasRelatedWork W3183948672 @default.
• W4386476503 hasRelatedWork W2143744720 @default.
• W4386476503 hasRelatedWork W2778153218 @default.
• W4386476503 hasRelatedWork W3110381201 @default.
• W4386476503 hasVolume "206" @default.
• W4386476503 isParatext "false" @default.
• W4386476503 isRetracted "false" @default.
• W4386476503 workType "article" @default.